Overview

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Status:
Completed
Trial end date:
2016-11-09
Target enrollment:
Participant gender:
Summary
Protocol G200712 is a Phase II, exploratory study to assess the effects of GTx-758 on serum prostate specific antigen (PSA) response ans serum PSA progression in men with Metastatic Castration Resistant Prostate Cancer (mCRPC) on Androgen Deprivation Therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists, or orchidectomy. This study will also assess the venous thromboembolism (VTE) risk of lower doses of GTx-758.
Phase:
Phase 2
Details
Lead Sponsor:
GTx
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate